RxDoctor Payments DataLook up a doctor →

Craig Wiesenhutter, MD

Rheumatology · Coeur D Alene, IDNPI 1205980422

Payments from drug & device makers

$78,632in general payments, 2019–2025

Across 463 payments — averaging $169.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$47K
  • Astrazeneca UK Limited$21K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Novartis$2K
  • Amgen$2K
  • Lilly USA, LLC$771
  • plus $3K from 21 others
$3,892in research payments, 2019–2025

Across 1 payment — averaging $3892.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$4K

What the payments were for

  • Food & beverage$6,69399%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,632 in reported general payments places this provider in the 85th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho

Medicare billing

Part B allowed, 2024
$1,435,491
Medicare patients
98
Services billed
125,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept40$389,533
Humira(Cf) PenAdalimumab12$270,340
RinvoqUpadacitinib16$136,360
Cimzia (2 Pack)Certolizumab Pegol12$90,375
Orencia ClickjectAbatacept13$73,738
BenlystaBelimumab11$61,599
Mycophenolate Mofetil43$7,021
MethotrexateMethotrexate Sodium245$5,851
Cevimeline Hcl17$4,065
Hydroxychloroquine Sulfate100$3,184
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$2,365
Leflunomide38$1,713
Prednisone174$1,135
Tramadol Hcl53$621
Trazodone Hcl37$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$594$136,36016 claims
UCB, Inc.Cimzia (2 Pack)$439$90,37512 claims
GSKBenlysta$168$61,59911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 rheumatology providers in Idaho.

Other rheumatology in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →